Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | CDC25A | P30304 | 2/20 | 0.36 |
| ▸ | CDC25B | P30305 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 4/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705239 | 0.64 | ACHE (0.39) | CDC25ACDC25BACHESTK17BHDAC3 | |
| SCHEMBL2371486 | 0.60 | — | — | |
| SCHEMBL6222320 | 0.59 | GAPDH (0.32) | — | |
| SCHEMBL25267221 | 0.57 | DRD2 (0.34) | LMNAMAOB | |
| SCHEMBL5196941 | 0.57 | TYMS (0.40) | CYP19A1CDC25ACDC25BIDO1ACHE | |
| SCHEMBL5196943 | 0.57 | TYMS (0.40) | CYP19A1CDC25ACDC25BIDO1ACHE | |
| SCHEMBL10551618 | 0.57 | MAOB (0.47) | CYP19A1ACHEMAPTRAB9ATDP1 | |
| SCHEMBL5111536 | 0.56 | MAOA (0.46) | GAACYP1A2MAOB | |
| SCHEMBL11106693 | 0.56 | TDP1 (0.56) | CDC25ACDC25BIDO1PTPN1MAPT | |
| SCHEMBL167093 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | CYP19A1 1682/4885CDC25A 4063/4885CDC25B 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.